Monomeric Insulin via Supramolecular PEGylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current insulin formulations, even 'rapid-acting' analogues, have delayed onset and prolonged duration of action due to their hexameric structure, which is unstable and prone to aggregation, failing to closely mimic endogenous insulin pharmacokinetics and leading to suboptimal glycemic control in diabetes management.
Innovation Solution
A stable monomeric insulin formulation is achieved through supramolecular PEGylation using CB[7]-PEG, which stabilizes insulin in a monomeric state, promoting faster diffusion and absorption, thereby reducing the risk of post-prandial hypoglycemia by using specific excipients like glycerol and phenoxyethanol to maintain at least 50% of insulin as monomers and minimize hexamer formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If insulin is formulated as hexamers to prevent aggregation, then stability is improved, but onset of action is delayed and duration is prolonged
Solution Approach 1:
The patent segments the insulin formulation into distinct association states (monomers, dimers, hexamers) with controlled proportions. By formulating insulin at concentrations and conditions that maintain a predominance of monomeric and dimeric forms while minimizing hexamers, the formulation achieves both stability and rapid action. The segmentation principle is applied by deliberately controlling the distribution of insulin association states rather than relying on a single dominant form.
Solution Approach 2:
The patent applies parameter changes by modifying formulation conditions including insulin concentration, pH, ionic strength, and the presence of specific excipients to shift the equilibrium between insulin association states. These parameter changes enable the formulation to maintain insulin primarily in monomeric and dimeric forms, achieving both stability and rapid pharmacokinetics without requiring high hexamer content.
2Stability of the object's composition
If zinc is added to stabilize hexameric state, then formulation stability is improved, but absorption rate is reduced
Solution Approach 1:
The patent extracts or removes zinc from the formulation to prevent hexamer stabilization. By eliminating zinc, the formulation avoids the formation of stable zinc-insulin hexamers that would slow absorption. This taking out principle directly addresses the contradiction by removing the substance (zinc) that causes hexamer stabilization, thereby enabling faster absorption while maintaining stability through alternative means.
Solution Approach 2:
The patent introduces alternative excipients that act as intermediaries to stabilize insulin in monomeric and dimeric forms without promoting hexamer formation. These intermediary substances provide the necessary stability function that would otherwise be provided by zinc-hexamer complexes, but without the detrimental effect on absorption rate.
3Speed
If insulin monomer is used to achieve fast action, then onset of action is improved, but aggregation occurs rapidly
Solution Approach 1:
The patent applies preliminary action by pre-formulating insulin in a state where monomers and dimers are stabilized through specific formulation conditions before administration. The formulation is prepared in advance with controlled concentration, pH, and excipients that prevent aggregation, so that when administered, the insulin is already in the desired monomeric/dimeric state ready for rapid absorption without requiring in vivo dissociation from aggregates.
Solution Approach 2:
The patent uses parameter changes including optimizing insulin concentration to sub-physiological levels, adjusting pH to specific ranges, and controlling ionic strength to maintain insulin in stable monomeric and dimeric forms. These parameter changes create a formulation environment where monomers remain stable and do not rapidly aggregate, enabling both fast onset and formulation stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves a faster onset and shorter duration of action, enhancing meal-time responsiveness and reducing the risk of hypoglycemic events, with stability extended over 100 hours without altering insulin activity, compared to commercial formulations which remain stable for only 10 hours.
Implementation Method 1
conjugation of a polyethylene glycol (PEG) chain to a cucubit[7]uril (CB[7]) creates a tool for non-covalent PEGylation using host-guest binding with the excipient CB[7]-PEG. CB[7]-PEG has strong binding affinities for terminal aromatic amino acids such the N-terminal phenylalanine found on insulin making it an ideal candidate for host-guest binding.
Implementation Method 2
phenol and meta-cresol stabilize the R6 insulin hexamer by forming hydrogen bonds between dimers. This suggests that even in the absence of zinc, the phenolic preservatives may contribute to higher order insulin structures that may slow absorption from the subcutaneous space.
Implementation Method 3
The formulation achieves a faster onset and shorter duration of action, enhancing meal-time responsiveness and reducing the risk of hypoglycemic events, with stability extended over 100 hours without altering insulin activity
Data Source
AI summary
Stable monomeric insulin formulations are enabled by supramolecular PEGylation of insulin or insulin analogues, and provide a method for treating diabetes, or managing or reducing blood glucose.